tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2012-2-5-13tumors-7Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРА ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА У БОЛЬНЫХ НЕМЕЛКОКЛЕТОЧНЫМ РАКОМ ЛЕГКОГО: 10 ЛЕТ СПУСТЯТюляндинС. А.

отделение клинической фармакологии, Каширское ш. 24, Москва, Россия 115478 Тел. (499) 324 98 44.

НосовД. А.Российский онкологический научный центр им. Н.Н. Блохина РАМНRussian Federation20121905201512513Copyright © Тюляндин С.А., Носов Д.А., 20152015Тюляндин С.А., Носов Д.А.Тюляндин С.А., Носов Д.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/7

Опыт применения ингибиторов тирозинкиназы рецептора эпидермального фактора роста (EGFR) насчитывает около 10 лет. За это время произошла серьезная эволюция наших представлений о месте и показаниях к назначению ингибиторов EGFR при немелкоклеточном раке легкого (НМРЛ). Эти лекарства были в первом ряду таргетных препаратов, идеология применения которых подразумевала точечное поражение мишени, имеющее важное значение для жизнедеятельности опухолевой клетки. Назначение таргетных препаратов показано только тем больным, у которых в опухоли содержится мишень поражения. Обнаружение активирующих мутаций в гене EGFR или мутаций, повышающих связывающую способность ингибиторов тирозинкиназы EGFR, позволило выделить тех (не более 10% от общего числа больных НМРЛ) больных, у которых наблюдается выраженный эффект от назначения этих препаратов. Таким образом, терапия ингибиторами EGFR стала таргетной не только по определению, но и по смыслу.

немелкоклеточный рак легкогорецептор эпидермального фактора ростагиперэкспрессиямутацияэрлотинибгефитинибReferencesДавыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Вестник РОНЦ им. Н.Н.Блохина РАМН, т. 21, приложение №1, 2010.Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Вестник РОНЦ им. Н.Н.Блохина РАМН, т. 21, приложение №1, 2010.Rusch, v. et al. Differential expression of the epidermal growth factor receptor and its ligands in primary nonsmall cell lung cancers and adjacent benign lung. Cancer Res. 53, 2379–2385 (1993).Rusch, v. et al. Differential expression of the epidermal growth factor receptor and its ligands in primary nonsmall cell lung cancers and adjacent benign lung. Cancer Res. 53, 2379–2385 (1993).Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21, 2237–2246 (2003).Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21, 2237–2246 (2003).Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149–2158 (2003).Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149–2158 (2003).Shepherd, F. A. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, 2095–2103 (2000).Shepherd, F. A. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, 2095–2103 (2000).Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132 (2005).Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132 (2005).Tsao, M. S. et al. Erlotinib in lung cancer— molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133–144 (2005).Tsao, M. S. et al. Erlotinib in lung cancer— molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133–144 (2005).Thatcher, N. et al. Gefitinib plus best supportive careThatcher, N. et al. Gefitinib plus best supportive carein previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527–1537 (2005).in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527–1537 (2005).Kim, E. S. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 372, 1809–1818 (2008) 10. Maruyama, R. et al. Phase III study, v-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 26, 4244–4252 (2008).Kim, E. S. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 372, 1809–1818 (2008) 10. Maruyama, R. et al. Phase III study, v-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 26, 4244–4252 (2008).Crinò, L. et al. Gefitinib versus vinorelbine in chemotherapynaive elderly patients with advanced non-smallcell lung cancer (INvITE): a randomized, phase II study. J. Clin. Oncol. 26, 4253–4260 (2008).Crinò, L. et al. Gefitinib versus vinorelbine in chemotherapynaive elderly patients with advanced non-smallcell lung cancer (INvITE): a randomized, phase II study. J. Clin. Oncol. 26, 4253–4260 (2008).Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial— INTACT 1. J. Clin. Oncol. 22, 777–784 (2004).Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial— INTACT 1. J. Clin. Oncol. 22, 777–784 (2004).Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial— INTACT 2. J. Clin. Oncol. 22, 785–794 (2004).Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial— INTACT 2. J. Clin. Oncol. 22, 785–794 (2004).Gatzemeier, U. et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25, 1545–1552 (2007).Gatzemeier, U. et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25, 1545–1552 (2007).Herbst, R. S. et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892–5899 (2005).Herbst, R. S. et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892–5899 (2005).Lynch T.J., Bell D.W., Sordella R. et al. Activating mutations in the epidermal growth factoe receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129-2139.Lynch T.J., Bell D.W., Sordella R. et al. Activating mutations in the epidermal growth factoe receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129-2139.Paez J.G., Janne P.A., Lee J.C. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.Paez J.G., Janne P.A., Lee J.C. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923, 2004.Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923, 2004.Hirsch, F. R. et al. Molecular predictors of outcome with gefitinib in a phase III placebo- controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24, 5034–5042 (2006).Hirsch, F. R. et al. Molecular predictors of outcome with gefitinib in a phase III placebo- controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24, 5034–5042 (2006).Inoue, A. et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J. Clin. Oncol. 27, 1394–1400 (2009).Inoue, A. et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J. Clin. Oncol. 27, 1394–1400 (2009).Sequist, L. v. et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26, 2442–2449 (2008).Sequist, L. v. et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26, 2442–2449 (2008).Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958–967 (2009).Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958–967 (2009).Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).Lee, J. S. et al. A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [abstract]. J. Thorac. Oncol. 4 (Suppl. 1), PRS.4 (2009).Lee, J. S. et al. A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [abstract]. J. Thorac. Oncol. 4 (Suppl. 1), PRS.4 (2009).Pirker, R. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525–1531 (2009).Pirker, R. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525–1531 (2009).Lynch, T. J. et al. Cetuximab and first-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J. Clin. Oncol. 28, 911–917 (2010).Lynch, T. J. et al. Cetuximab and first-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J. Clin. Oncol. 28, 911–917 (2010).

The authors declare that there are no conflicts of interest present.